Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 305

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains

Open access
Mirguet, Olivier, Gosmini, Romain, Toum, Jérôme, Clément, Catherine A., Barnathan, Mélanie, Brusq, Jean-Marie, Mordaunt, Jacqueline E., Grimes, Richard M., Crowe, Miriam, Pineau, Olivier, Ajakane, Myriam, Daugan, Alain, Jeffrey, Phillip, Cutler, Leanne, Haynes, Andrea C., Smithers, Nicholas N., Chung, Chun-wa, Bamborough, Paul, Uings, Iain J., Lewis, Antonia, Witherington, Jason, Parr, Nigel, Prinjha, Rab K., Nicodème, Edwige·2013·Journal of Medicinal Chemistry

Abstract

The bromo and extra C-terminal domain (BET) family of bromodomains are involved in binding epigenetic marks on histone proteins, more specifically acetylated lysine residues. This paper describes the discovery and structure-activity relationships (SAR) of potent benzodiazepine inhibitors that disrupt the function of the BET family of bromodomains (BRD2, BRD3, and BRD4). This work has yielded a potent, selective compound I-BET762 that is now under evaluation in a phase I/II clinical trial for nuclear protein in testis (NUT) midline carcinoma and other cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/jm401088k

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

Metadata

Authors
Mirguet, O., Gosmini, R., Toum, J., Clément, C. A., Barnathan, M., Brusq, J.-M., Mordaunt, J. E., Grimes, R. M., Crowe, M., Pineau, O., Ajakane, M., Daugan, A., Jeffrey, P., Cutler, L., Haynes, A. C., Smithers, N. N., Chung, C.-W., Bamborough, P., Uings, I. J., Lewis, A., Witherington, J., Parr, N., Prinjha, R. K., & Nicodème, E.
Venue
Journal of Medicinal Chemistry
Published
2013-09-25
Volume
56
Issue
19
Pages
7501-7515
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2032365395
Cited by
305
References
26
FWCI
11.70
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.